Abstract:Abstract Abstract 597 Resistance against tyrosine kinase inhibitors (TKI) has been an important issue in treatment for chronic myeloid leukemia (CML) and Ph-positive acute lymphoblastic leukemia (ALL), and it mainly result from BCR-ABL1 kinase domain mutation. Many studies have focused on the issue, however, characteristics of origin and evolution of BCR-ABL1 mutant clones remains unclear. In this study, we analyzed BCR-ABL1 mutations within the kinase domain for 189 bone marrow or peripheral blood samples, which were collected from 151 cases of CML or Ph-positive ALL. All samples were taken prior to and in the process of TKI treatment, followed by nested PCR and sequencing. Partial of the samples were cloned and sequenced to determine the composition and proportion of mutant clones. Quantification of BCR-ABL1 fusion gene expression was performed according to Europe Against Cancer Program protocol. We reported here that (i) Totally 43 patients harbored 27 BCR-ABL1 mutations, consisting of 24 point mutations, two frameshift mutations (1086_1087delAG/D363fsX380 and 1330delG/D444fsX452) and one in-frame insertion mutation (1073-1074insAAA/357-358insK); (ii) Both deletion mutations only occurred transiently with very low level of BCR-ABL1 expression (0.020% and 0.013% respectively), whereas the insertion mutation was detected in a nearly 100% of mutant clone with completely resistant against the Imatinib; (iii) One G250E and one L370Q mutant clones were detected in 4.1% (2/49) of the patients with BCR-ABL1 expression at low level (0.55% and 0.16% respectively) prior to TKI therapy. Following TKI treatment, resistant mutations were detected in 75.4% (43/57) of patients who presented drug resistance clinically; (iv) Coexistence of multiple mutations in a single clone or temporal evolution of different mutation clones were found in 6 patients, 4 of whom underwent reduction of drug dosage. One clone carrying E355G and T315I mutations simultaneously was detected in patient No.1, and proportion of the double mutant clone increased following incidence of TKI resistance. Two different clones carrying G250E and M351T respectively were detected in Patient No.2. The proportion of M351T clone with less resistance decreased, and the proportion of G250E clone with moderate resistance went up during Imatinib therapy. A similar phenomenon was seen in Patient No.6 carrying the mutation of Q252H and T315I. Two different clones carrying E275D and D444fsX452 respectively were detected at low proportion (11.3% and 15.1% respectively) and low BCR-ABL1 expression 0.013% in Patient No.3, and surprisingly, the two clones disappeared and a T315I clone emerged and became dominant a month after with CML progressed toward the blast crisis; (v) Three different TKI-resistant clones, Y253H, F359V and F486S, were simultaneously detected with a high BCR-ABL1 expression (142%) in a Ph positive ALL (Patient No.4), who is in follow-up presently; (vi)Two different clones carrying G250E and T315I respectively were detected in Patient No.5. The proportion of G250E clone with moderate resistance decreased, whereas frequency of the T315I clone with highly resistance increased following Imatinib and Dasatinib administration. This patient received allo-geneic bone marrow transplantation (BMT) due to TKI resistance, and thereafter the D363fsX380 mutation without kinase activity was transiently detected with very low level of BCR-ABL1 expression, and Dasatinib sensitivity was restored; (vii) Clone and sequencing also find that mutant clones were randomly occurred with low percentage even in pre TKI treatment samples and K562 cell line. These mutations could be common or uncommon resistant mutations, and also can be synonymous mutations or even loss of kinase activity mutations. Taken together, our data indicate that (i) Origin of mutant clones may be random in samples with and without TKI treatment; (ii) The mutation clones always have lower kinase activity than wild type clone, thus it can not evolution into the major clone in the absence of TKI; (iii) The TKI-resistant clone may acquire proliferating advantage, and evolve into the dominant clone under the pressure of TKI; and (iv) We further propose that temporary interruption of TKI and switching to non-selective therapy can be a valid therapeutic option for anti-resistant strategy. Disclosures: No relevant conflicts of interest to declare.

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia

Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia

Resistance mutations in CML and how we approach them

Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms

Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

Mechanisms of Resistance to Targeted Therapies in AML

Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia

Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia

Clonal Evolution Of Bcr-Abl1 Kinase Domain Mutation In Tyrosine Kinase Inhibitor Treatment Patient

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia

Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors